智通财经APP获悉，艾伯维(ABBV.US)（AbbVie）与Xilio Therapeutics今日宣布达成一项合作及选择性许可协议，双方将利用Xilio的专有技术，共同开发新型肿瘤激活、基于抗体的免疫疗法，其中包括掩蔽型T细胞接合器。Xilio正通过其专有且经过临床验证的肿瘤激活平台，推进一系列完全自主研发的新型掩蔽型T细胞接合器分子，这些分子具备条件性半衰期调控功能，旨在实现强效的局部T细胞激活与肿瘤细胞破坏，从而最大限度地减少全身性不良事件并改善治疗指数。
这些项目包括采用Xilio先进的肿瘤激活型细胞接合器（ATACR）设计的双特异性分子，这类分子由具有掩蔽型CD3靶向域的T细胞接合器构成；以及采用Xilio选择性效应增强型细胞接合器（SEECR）设计的三特异性分子。SEECR是在ATACR的基础上增加了共刺激信号，以进一步增强药效及T细胞激活。目前，Xilio正在推进三个完全自主研发的临床前项目，这些项目的掩蔽型T细胞接合器分子分别针对以下肿瘤相关抗原：PSMA、CLDN18.2和STEAP1。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.